Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
14 juin 2022 07h00 HE
|
Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 juin 2022 16h02 HE
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul...
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
03 juin 2022 16h01 HE
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 16h01 HE
|
Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2022 16h01 HE
|
Freeline Therapeutics
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired...
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
02 mai 2022 17h10 HE
|
Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Freeline Appoints Paul Schneider as Chief Financial Officer
19 avr. 2022 08h01 HE
|
Freeline Therapeutics
LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that Paul M. Schneider has been appointed Chief Financial...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 avr. 2022 16h01 HE
|
Freeline Therapeutics
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on March 31, 2022, the Company granted its newly hired...
Freeline Reports Full Year 2021 Financial Results and Business Highlights
31 mars 2022 16h01 HE
|
Freeline Therapeutics
Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Companythrough key data readouts across...
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
24 mars 2022 07h00 HE
|
Freeline Therapeutics
Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline...